Khondrion announces first clinical trial

27/5/15 - Khondrion, the Dutch biopharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, announces today the initiation of a Phase 1 Clinical Trial with its frontrunner compound KH176. Read the full press release.